Therapeutic area intelligence for Pneumococcal Vaccine with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 2

Companies

Merck →

Pfizer →

Assets

Adults Aged →

CAPVAXIVE →

Recent signals(3)

CompetitiveAugust 4, 2026

New Pneumococcal Vaccine Study Initiated for Adults Aged 18 and Older

A study is underway to evaluate the safety and immune response of new pneumococcal vaccine candidates in adults, including those aged 50 and older.

RegulatoryJune 19, 2026

FDA Approves CAPVAXIVE for At-Risk Children and Adolescents

The FDA has approved an expanded indication for CAPVAXIVE to include children and adolescents aged 2-17 at increased risk for pneumococcal disease.

ClinicalJune 16, 2026

Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Infectious Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.